GAITHERSBURG, MD – October 1, 2024 – miRecule, a biopharmaceutical company focused on developing antibody RNA conjugate-based therapeutics for rare genetic diseases and other conditions, today announced the issuance of U.S. Patent No. 12,104,157, titled “Targeted Inhibition Using Engineered Oligonucleotides.” This patent broadly covers one of the company’s lead RNA therapeutics and other engineered oligonucleotides.
The ‘157 patent covers engineered oligonucleotides that are modified forms of miR-30 miRNA with superior binding properties. It also covers vectors, kits, and pharmaceutical compositions comprising these oligonucleotides. The patent is expected to expire in 2041.
The newly issued patent strengthens miRecule’s intellectual property portfolio around its core programs and provides broad protection for the company’s technology.
“We are pleased to announce the issuance of this important patent, which further strengthens our IP position,” said Anthony Saleh, Chief Executive Officer of miRecule. “This patent provides broad coverage for our engineered oligonucleotides, which we believe have the potential to be developed into a new class of targeted therapeutics.”